Completed
Response depends on agitation phenotype Affective vs. Dysexecutive
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Treatment Development for Neuropsychiatric Disturbances in Dementia: Past, Present, Future - Grand Rounds
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Learning objectives
- 3 Facing reality: balancing "cure" with "care"
- 4 Auguste D: hospitalized for delusions and change in personality, not cognitive impairment
- 5 NPS are UNIVERSAL (97%) & fluctuate Cache County Dementia Progression Study
- 6 Eco-psychosocial interventions behavioral, environmental, caregiver focused
- 7 Medication treatment development for NPS The past: BEFORE 2011
- 8 Medication Rxs disappointing when using existing DSM/ICD phenotypes
- 9 Antipsychotics: small benefit Antipsychotics carry "BLACK BOX" warning
- 10 Challenges of DSM-IV phenotypes
- 11 Overlap of symptoms Cache County Dementia Progression Study
- 12 Hypotheses based on etiology
- 13 The future: 2023 and beyond Novel medications for agitation
- 14 Serotonin system loss in AD early but not universal, interacts with ATN
- 15 Response limited to a subgroup HETEROGENEITY
- 16 Response depends on agitation phenotype Affective vs. Dysexecutive
- 17 Breaking down the heterogeneity of NPS The future: 2023 and beyond
